Everything you need to know about semaglutide — how it works, dosing, clinical results, side effects, and which brand might be right for your goals.
Semaglutide is a medication that belongs to a class of drugs called GLP-1 receptor agonists. It mimics a natural hormone your body already makes — glucagon-like peptide-1 (GLP-1) — which plays a central role in controlling blood sugar and appetite. The FDA approved semaglutide in 2009, but its weight-loss potential wasn't widely recognized until years later when clinical trials showed remarkable results.
Semaglutide comes under three brand names, each with a specific approved use:
What's important to understand: all three contain the exact same active ingredient. The differences are in dosing, indication, and formulation.
Semaglutide's mechanism is elegant. When you inject it, it travels through your bloodstream and binds to GLP-1 receptors in your brain and digestive system. This triggers a cascade of effects that work together:
1. Slows gastric emptying: Your stomach empties more slowly, so food stays with you longer and you feel full faster.
2. Reduces appetite signals: It acts on the hypothalamus (your brain's hunger center), making you genuinely less interested in food.
3. Improves insulin sensitivity: Your cells respond better to insulin, helping stabilize blood sugar and reduce cravings.
The result? Most people report eating less without feeling deprived. Many describe it as if their brain finally got the signal that they've eaten enough.
While the active ingredient is identical, semaglutide's different brands are marketed for different purposes. Here's how they compare:
| Brand | Approved For | Dose Range | Route | FDA Approval |
|---|---|---|---|---|
| Ozempic | Type 2 diabetes | 0.5–2 mg/week | Weekly injection | 2009 |
| Wegovy | Chronic weight management | 0.25–2.4 mg/week | Weekly injection | 2021 |
| Rybelsus | Type 2 diabetes | 3–14 mg daily | Oral tablet | 2019 |
The STEP trials — four landmark studies conducted between 2018 and 2020 — demonstrated semaglutide's effectiveness for weight loss. These were large, rigorous trials involving thousands of participants followed for 68 weeks.
Participants on the highest dose of semaglutide (2.4 mg weekly) lost an average of 15% of their body weight. Some lost significantly more. For a 200-pound person, that's 30 pounds on average — far exceeding results from diet and exercise alone.
STEP-1 focused on people without diabetes, STEP-2 on those with previous weight-loss surgery, STEP-3 on people with diabetes, and STEP-4 on cardiovascular outcomes. Across all four trials, semaglutide consistently beat placebo and showed sustainable weight loss.
Importantly, people didn't regain weight during the treatment period. When people stopped taking semaglutide in follow-up studies, weight typically came back — which is why it's positioned as a chronic management tool, not a quick fix.
For Wegovy (weight loss), the typical titration schedule looks like this:
| Week | Dose | Notes |
|---|---|---|
| Week 1–4 | 0.25 mg | Once weekly injection. Lets your body adjust. |
| Week 5–8 | 0.5 mg | Increase if well tolerated. |
| Week 9–12 | 1 mg | Continue adjusting. |
| Week 13–16 | 1.7 mg | Most people reach their target here. |
| Week 17+ | 2.4 mg | The maximum dose; optional if 1.7 mg is effective. |
You inject once per week, always on the same day. Most people choose their thigh, abdomen, or back of the arm. The needles are short and thin — many users report the injection itself is barely noticeable.
Semaglutide does have side effects. Most are manageable, but they're worth understanding before starting.
Nausea: About 25% of people experience mild to moderate nausea, especially in the first few weeks. It usually improves as your body adjusts or with slower titration.
Gastrointestinal issues: Diarrhea, constipation, and vomiting occur in a portion of users. Often resolved by staying hydrated and eating smaller meals.
Injection site reactions: Mild redness or irritation at injection sites is common and usually temporary.
Semaglutide carries an FDA boxed warning for risk of thyroid cancer and C-cell tumors in animal studies. It should not be used in people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2. Anyone with thyroid concerns should discuss this with their doctor.
Rarer but serious side effects include acute pancreatitis, severe hypoglycemia (if combined with diabetes medications), and gallbladder problems. About 15% of semaglutide users report some gallbladder-related symptoms. Most resolve on their own, but in rare cases, gallbladder removal has been necessary.
One often-overlooked concern is "semaglutide-induced" nutritional deficiency. Because you're eating significantly less, you need to be intentional about protein and micronutrients. Many providers recommend supplementation or working with a nutritionist.
Cost is often the biggest barrier to semaglutide use. Brand-name Wegovy typically costs $1,000–$1,300 per month without insurance. Ozempic for diabetes may be covered by insurance if you have type 2 diabetes, but Wegovy for weight loss rarely is — most insurers classify it as cosmetic.
Manufacturer savings: Novo Nordisk (maker of Wegovy) offers a $99/month patient assistance program if you meet income limits.
Compounded semaglutide: Unbranded compounded versions cost $69–$199 per month at some pharmacies. Quality varies; verify that your provider uses a reputable compounding pharmacy.
GLP-1 telehealth programs: Many subscription telemedicine services like Calibrate, Found, and Ro Body offer semaglutide at lower out-of-pocket costs (typically $200–$600/month), often with insurance benefits.
For more on how to navigate insurance and find affordable semaglutide, see our GLP-1 insurance guide or compounded GLP-1 article.
The FDA approves Wegovy for adults with:
Semaglutide works best for people who:
It's less ideal for people with a strong family history of thyroid cancer, those unable to afford ongoing treatment, or anyone unwilling to commit to lifestyle changes alongside medication.
No. Both are GLP-1 receptor agonists, but tirzepatide is a different molecule that also targets GIP receptors. Early evidence suggests tirzepatide may produce slightly greater weight loss (18–22% vs. 15% for semaglutide), but semaglutide has longer real-world data and a longer safety track record. Neither is universally "better" — it depends on individual response and tolerance.
Yes. In fact, Ozempic is primarily marketed for diabetes. If you have diabetes and want to lose weight, Ozempic or a higher-dose formulation (like Wegovy) can serve both purposes. Always coordinate with your doctor, as semaglutide lowers blood sugar — you may need to adjust other diabetes medications to avoid hypoglycemia.
Weight typically returns over several months. This is why semaglutide is positioned as a chronic management tool. Studies show most people regain 50% of the weight they lost within a year of stopping — though many don't regain all of it if they maintain lifestyle changes. Some people stay on it indefinitely; others take breaks and restart.
Semaglutide can interact with diabetes medications (increasing hypoglycemia risk), oral contraceptives (it slows gastric emptying, potentially reducing absorption), and some other drugs. It also increases heart rate slightly. Always give your doctor a complete medication list. Don't assume semaglutide is safe with other drugs without checking.
The longest rigorous data we have is 68 weeks from the STEP trials. Longer-term safety is still being studied. The thyroid cancer warning applies to animal data, not human data, but it's taken seriously by the FDA. For most people, semaglutide appears safe, but it's not risk-free and should only be used under medical supervision. Those with personal or family thyroid cancer history should avoid it.
Exclusive provider discounts, healthy living guides for your GLP-1 journey, and the latest breakthroughs in peptide science — delivered free.
No spam ever. Unsubscribe anytime.
GLP1Authority.com is an independent review site. We may receive compensation when you click certain links. See our affiliate disclosure for details.
Not sure which GLP-1 program is right for you?
2 minutes. No email required.